Bahl & Gaynor Inc. Purchases 278 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 125,877 shares of the medical instruments supplier’s stock after buying an additional 278 shares during the quarter. Bahl & Gaynor Inc. owned 0.56% of LeMaitre Vascular worth $8,353,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LMAT. Conestoga Capital Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 0.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,932,917 shares of the medical instruments supplier’s stock valued at $128,268,000 after purchasing an additional 4,946 shares in the last quarter. Vanguard Group Inc. raised its position in LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock valued at $103,112,000 after buying an additional 4,964 shares during the last quarter. Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 2.3% in the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock valued at $71,515,000 after purchasing an additional 28,720 shares during the last quarter. Ranger Investment Management L.P. grew its holdings in LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after purchasing an additional 13,681 shares during the period. Finally, Congress Asset Management Co. MA increased its position in LeMaitre Vascular by 12.0% during the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after buying an additional 71,411 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Barrington Research raised their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. JMP Securities raised their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday, July 17th. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their target price for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The disclosure for this sale can be found here. Insiders have sold a total of 127,437 shares of company stock worth $10,076,242 in the last 90 days. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded up $1.98 on Tuesday, hitting $90.36. The company’s stock had a trading volume of 67,055 shares, compared to its average volume of 122,855. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $90.56. The company has a market capitalization of $2.03 billion, a PE ratio of 59.32, a PEG ratio of 2.63 and a beta of 0.89. The stock’s 50 day moving average is $81.17 and its 200-day moving average is $69.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same quarter in the previous year, the firm posted $0.27 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.